ARNA / Arena Pharmaceuticals Inc - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 000-31161 Arena Pharmaceuticals, Inc. (Exact name of registrant as specified in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 3 FORM S-8 REGISTRATION STATEMENT NO. 333-160329 FORM S-8 REGISTRATION STATEMENT NO. 333-182238 FORM S-8 REGISTRATION STATEMENT NO. 333-189213 FORM S

Registration No. 333-160329 Registration No. 333-182238 Registration No. 333-189213 Registration No. 333-212012 Registration No. 333-214529 Registration No. 333-217805 Registration No. 333-218905 Registration No. 333-225608 Registration No. 333-232142 Registration No. 333-239330 Registration No. 333-257053 Registration No. 333-135398 Registration No. 333-204999 Registration No. 333-45330 Registrat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 3 FORM S-8 REGISTRATION STATEMENT NO. 333-160329 FORM S-8 REGISTRATION STATEMENT NO. 333-182238 FORM S-8 REGISTRATION STATEMENT NO. 333-189213 FORM S

Registration No. 333-160329 Registration No. 333-182238 Registration No. 333-189213 Registration No. 333-212012 Registration No. 333-214529 Registration No. 333-217805 Registration No. 333-218905 Registration No. 333-225608 Registration No. 333-232142 Registration No. 333-239330 Registration No. 333-257053 Registration No. 333-135398 Registration No. 333-204999 Registration No. 333-45330 Registrat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 3 FORM S-8 REGISTRATION STATEMENT NO. 333-160329 FORM S-8 REGISTRATION STATEMENT NO. 333-182238 FORM S-8 REGISTRATION STATEMENT NO. 333-189213 FORM S

S-8 POS 1 brhc10035054s-8pos.htm S-8 POS Registration No. 333-160329 Registration No. 333-182238 Registration No. 333-189213 Registration No. 333-212012 Registration No. 333-214529 Registration No. 333-217805 Registration No. 333-218905 Registration No. 333-225608 Registration No. 333-232142 Registration No. 333-239330 Registration No. 333-257053 Registration No. 333-135398 Registration No. 333-20

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 3 FORM S-8 REGISTRATION STATEMENT NO. 333-160329 FORM S-8 REGISTRATION STATEMENT NO. 333-182238 FORM S-8 REGISTRATION STATEMENT NO. 333-189213 FORM S

Registration No. 333-160329 Registration No. 333-182238 Registration No. 333-189213 Registration No. 333-212012 Registration No. 333-214529 Registration No. 333-217805 Registration No. 333-218905 Registration No. 333-225608 Registration No. 333-232142 Registration No. 333-239330 Registration No. 333-257053 Registration No. 333-135398 Registration No. 333-204999 Registration No. 333-45330 Registrat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 3 FORM S-8 REGISTRATION STATEMENT NO. 333-160329 FORM S-8 REGISTRATION STATEMENT NO. 333-182238 FORM S-8 REGISTRATION STATEMENT NO. 333-189213 FORM S

Registration No. 333-160329 Registration No. 333-182238 Registration No. 333-189213 Registration No. 333-212012 Registration No. 333-214529 Registration No. 333-217805 Registration No. 333-218905 Registration No. 333-225608 Registration No. 333-232142 Registration No. 333-239330 Registration No. 333-257053 Registration No. 333-135398 Registration No. 333-204999 Registration No. 333-45330 Registrat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 FORM S-3 REGISTRATION STATEMENT NO. 333-112542 FORM S-3 REGISTRATION STATEMENT NO. 333-136023 FORM S-3 REGISTRATION STATEMENT NO. 333-160983 FORM S

Registration No. 333-112542 Registration No. 333-136023 Registration No. 333-160983 Registration No. 333-167498 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT NO. 333-112542 FORM S-3 REGISTRATION STATEMENT NO. 333-136023 FORM S-3 REGISTRATION STATEMENT NO. 333-160983 FORM S-3 REGISTRATION STATEMENT NO. 333-1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 FORM S-3 REGISTRATION STATEMENT NO. 333-112542 FORM S-3 REGISTRATION STATEMENT NO. 333-136023 FORM S-3 REGISTRATION STATEMENT NO. 333-160983 FORM S

Registration No. 333-112542 Registration No. 333-136023 Registration No. 333-160983 Registration No. 333-167498 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT NO. 333-112542 FORM S-3 REGISTRATION STATEMENT NO. 333-136023 FORM S-3 REGISTRATION STATEMENT NO. 333-160983 FORM S-3 REGISTRATION STATEMENT NO. 333-1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 FORM S-3 REGISTRATION STATEMENT NO. 333-112542 FORM S-3 REGISTRATION STATEMENT NO. 333-136023 FORM S-3 REGISTRATION STATEMENT NO. 333-160983 FORM S

Registration No. 333-112542 Registration No. 333-136023 Registration No. 333-160983 Registration No. 333-167498 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT NO. 333-112542 FORM S-3 REGISTRATION STATEMENT NO. 333-136023 FORM S-3 REGISTRATION STATEMENT NO. 333-160983 FORM S-3 REGISTRATION STATEMENT NO. 333-1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 3 FORM S-8 REGISTRATION STATEMENT NO. 333-160329 FORM S-8 REGISTRATION STATEMENT NO. 333-182238 FORM S-8 REGISTRATION STATEMENT NO. 333-189213 FORM S

S-8 POS 1 brhc10035054s-8pos.htm S-8 POS Registration No. 333-160329 Registration No. 333-182238 Registration No. 333-189213 Registration No. 333-212012 Registration No. 333-214529 Registration No. 333-217805 Registration No. 333-218905 Registration No. 333-225608 Registration No. 333-232142 Registration No. 333-239330 Registration No. 333-257053 Registration No. 333-135398 Registration No. 333-20

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 FORM S-3 REGISTRATION STATEMENT NO. 333- 236717 THE SECURITIES ACT OF 1933 Arena Pharmaceuticals, Inc. (Exact name of registrant as specified in it

Registration No. 333-236717 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT NO. 333- 236717 UNDER THE SECURITIES ACT OF 1933 Arena Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2908305 (State or other jurisdiction of incorporation or organization) (I.R.S Employer Ide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 3 FORM S-8 REGISTRATION STATEMENT NO. 333-160329 FORM S-8 REGISTRATION STATEMENT NO. 333-182238 FORM S-8 REGISTRATION STATEMENT NO. 333-189213 FORM S

Registration No. 333-160329 Registration No. 333-182238 Registration No. 333-189213 Registration No. 333-212012 Registration No. 333-214529 Registration No. 333-217805 Registration No. 333-218905 Registration No. 333-225608 Registration No. 333-232142 Registration No. 333-239330 Registration No. 333-257053 Registration No. 333-135398 Registration No. 333-204999 Registration No. 333-45330 Registrat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 3 FORM S-8 REGISTRATION STATEMENT NO. 333-160329 FORM S-8 REGISTRATION STATEMENT NO. 333-182238 FORM S-8 REGISTRATION STATEMENT NO. 333-189213 FORM S

Registration No. 333-160329 Registration No. 333-182238 Registration No. 333-189213 Registration No. 333-212012 Registration No. 333-214529 Registration No. 333-217805 Registration No. 333-218905 Registration No. 333-225608 Registration No. 333-232142 Registration No. 333-239330 Registration No. 333-257053 Registration No. 333-135398 Registration No. 333-204999 Registration No. 333-45330 Registrat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 FORM S-3 REGISTRATION STATEMENT NO. 333-112542 FORM S-3 REGISTRATION STATEMENT NO. 333-136023 FORM S-3 REGISTRATION STATEMENT NO. 333-160983 FORM S

Registration No. 333-112542 Registration No. 333-136023 Registration No. 333-160983 Registration No. 333-167498 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT NO. 333-112542 FORM S-3 REGISTRATION STATEMENT NO. 333-136023 FORM S-3 REGISTRATION STATEMENT NO. 333-160983 FORM S-3 REGISTRATION STATEMENT NO. 333-1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 3 FORM S-8 REGISTRATION STATEMENT NO. 333-160329 FORM S-8 REGISTRATION STATEMENT NO. 333-182238 FORM S-8 REGISTRATION STATEMENT NO. 333-189213 FORM S

Registration No. 333-160329 Registration No. 333-182238 Registration No. 333-189213 Registration No. 333-212012 Registration No. 333-214529 Registration No. 333-217805 Registration No. 333-218905 Registration No. 333-225608 Registration No. 333-232142 Registration No. 333-239330 Registration No. 333-257053 Registration No. 333-135398 Registration No. 333-204999 Registration No. 333-45330 Registrat

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 March 11, 2022 Date of Report (Date of earliest event reported) Arena Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-31161 23-2908305 (State or Other Jurisdiction of Incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 3 FORM S-8 REGISTRATION STATEMENT NO. 333-160329 FORM S-8 REGISTRATION STATEMENT NO. 333-182238 FORM S-8 REGISTRATION STATEMENT NO. 333-189213 FORM S

Registration No. 333-160329 Registration No. 333-182238 Registration No. 333-189213 Registration No. 333-212012 Registration No. 333-214529 Registration No. 333-217805 Registration No. 333-218905 Registration No. 333-225608 Registration No. 333-232142 Registration No. 333-239330 Registration No. 333-257053 Registration No. 333-135398 Registration No. 333-204999 Registration No. 333-45330 Registrat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 3 FORM S-8 REGISTRATION STATEMENT NO. 333-160329 FORM S-8 REGISTRATION STATEMENT NO. 333-182238 FORM S-8 REGISTRATION STATEMENT NO. 333-189213 FORM S

Registration No. 333-160329 Registration No. 333-182238 Registration No. 333-189213 Registration No. 333-212012 Registration No. 333-214529 Registration No. 333-217805 Registration No. 333-218905 Registration No. 333-225608 Registration No. 333-232142 Registration No. 333-239330 Registration No. 333-257053 Registration No. 333-135398 Registration No. 333-204999 Registration No. 333-45330 Registrat

AMENDED AND RESTATED BYLAWS OF ARENA PHARMACEUTICALS, INC. ARTICLE I OFFICES

Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ARENA PHARMACEUTICALS, INC. ARTICLE I OFFICES SECTION 1.1. REGISTERED OFFICE. The registered office of the corporation shall be established and maintained at the office of The Corporation Trust Company, 1209 Orange Street, Corporation Trust Center, Wilmington, Delaware 19801, and said corporation shall be the registered agent of this corporation in charge

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION ARENA PHARMACEUTICALS, INC.

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ARENA PHARMACEUTICALS, INC. 1. The name of this corporation is: Arena Pharmaceuticals, Inc. (hereinafter, this ?Corporation?). 2. The address of its registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle. The name of its registered agent at such addr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 3 FORM S-8 REGISTRATION STATEMENT NO. 333-160329 FORM S-8 REGISTRATION STATEMENT NO. 333-182238 FORM S-8 REGISTRATION STATEMENT NO. 333-189213 FORM S

Registration No. 333-160329 Registration No. 333-182238 Registration No. 333-189213 Registration No. 333-212012 Registration No. 333-214529 Registration No. 333-217805 Registration No. 333-218905 Registration No. 333-225608 Registration No. 333-232142 Registration No. 333-239330 Registration No. 333-257053 Registration No. 333-135398 Registration No. 333-204999 Registration No. 333-45330 Registrat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 3 FORM S-8 REGISTRATION STATEMENT NO. 333-160329 FORM S-8 REGISTRATION STATEMENT NO. 333-182238 FORM S-8 REGISTRATION STATEMENT NO. 333-189213 FORM S

Registration No. 333-160329 Registration No. 333-182238 Registration No. 333-189213 Registration No. 333-212012 Registration No. 333-214529 Registration No. 333-217805 Registration No. 333-218905 Registration No. 333-225608 Registration No. 333-232142 Registration No. 333-239330 Registration No. 333-257053 Registration No. 333-135398 Registration No. 333-204999 Registration No. 333-45330 Registrat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 3 FORM S-8 REGISTRATION STATEMENT NO. 333-160329 FORM S-8 REGISTRATION STATEMENT NO. 333-182238 FORM S-8 REGISTRATION STATEMENT NO. 333-189213 FORM S

Registration No. 333-160329 Registration No. 333-182238 Registration No. 333-189213 Registration No. 333-212012 Registration No. 333-214529 Registration No. 333-217805 Registration No. 333-218905 Registration No. 333-225608 Registration No. 333-232142 Registration No. 333-239330 Registration No. 333-257053 Registration No. 333-135398 Registration No. 333-204999 Registration No. 333-45330 Registrat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 3 FORM S-8 REGISTRATION STATEMENT NO. 333-160329 FORM S-8 REGISTRATION STATEMENT NO. 333-182238 FORM S-8 REGISTRATION STATEMENT NO. 333-189213 FORM S

S-8 POS 1 brhc10035054s-8pos.htm S-8 POS Registration No. 333-160329 Registration No. 333-182238 Registration No. 333-189213 Registration No. 333-212012 Registration No. 333-214529 Registration No. 333-217805 Registration No. 333-218905 Registration No. 333-225608 Registration No. 333-232142 Registration No. 333-239330 Registration No. 333-257053 Registration No. 333-135398 Registration No. 333-20

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 3 FORM S-8 REGISTRATION STATEMENT NO. 333-160329 FORM S-8 REGISTRATION STATEMENT NO. 333-182238 FORM S-8 REGISTRATION STATEMENT NO. 333-189213 FORM S

Registration No. 333-160329 Registration No. 333-182238 Registration No. 333-189213 Registration No. 333-212012 Registration No. 333-214529 Registration No. 333-217805 Registration No. 333-218905 Registration No. 333-225608 Registration No. 333-232142 Registration No. 333-239330 Registration No. 333-257053 Registration No. 333-135398 Registration No. 333-204999 Registration No. 333-45330 Registrat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 3 FORM S-8 REGISTRATION STATEMENT NO. 333-160329 FORM S-8 REGISTRATION STATEMENT NO. 333-182238 FORM S-8 REGISTRATION STATEMENT NO. 333-189213 FORM S

Registration No. 333-160329 Registration No. 333-182238 Registration No. 333-189213 Registration No. 333-212012 Registration No. 333-214529 Registration No. 333-217805 Registration No. 333-218905 Registration No. 333-225608 Registration No. 333-232142 Registration No. 333-239330 Registration No. 333-257053 Registration No. 333-135398 Registration No. 333-204999 Registration No. 333-45330 Registrat

LBPH / Longboard Pharmaceuticals Inc / ARENA PHARMACEUTICALS INC - SC 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBE

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2022 Arena Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-31161 23-2908305 (State or other Jurisdiction of Incorporation) (Commissi

Omnibus Amendment to the Leases for Buildings D,E, F and G between BMR-6114-6154 Nancy Ridge Drive LLC and Arena for 6114, 6118, 6122, 6124, 6126, and 6154 Nancy Ridge Drive, San Diego, California

Exhibit 10.5 OMNIBUS AMENDMENT TO LEASES FOR BUILDINGS D, E, F AND G THIS OMNIBUS AMENDMENT TO LEASES FOR BUILDINGS D, E, F AND G (this ?Amendment?), made effective as of this 27th day of January, 2022 (?Effective Date?), is by and among BMR-6114-6154 Nancy Ridge Drive LP, a Delaware limited partnership (?Building D, E and G Landlord?), and BMR-6122-6126 Nancy Ridge Drive LP, a Delaware limited pa

Second Amended and Restated Severance Benefit Plan

Exhibit 10.29 ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED SEVERANCE BENEFIT PLAN Introduction. The Arena Pharmaceuticals, Inc. Amended and Restated Severance Benefit Plan originally effective on January 20, 2006 and amended and restated on May 9, 2016 and further amended on June 15, 2016, August 15, 2016, March 20, 2017, October 31, 2018, November 26, 2018, January 4, 2019, and June 11, 2021

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-31161 ARENA PH

Arena Pharmaceuticals, Inc. Amended and Restated 2021 Long-Term Incentive Plan, as amended as of February 8, 2022

Exhibit 10.53 ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN Adopted by the Compensation Committee: April 19, 2021 Approved by the Stockholders: June 11, 2021 Amended and Restated by the Compensation Committee: February 8, 2022 1.General. (a)Successor to and Continuation of 2020 Plan. The Plan is the successor to and continuation of the 2020 Plan. As of the Effective Date: (i) no additi

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of Arena Pharmaceuticals, Inc. As of December 31, 2021 125 Royalty Inc., a Delaware corporation 356 Royalty Inc., a Delaware corporation Arena Pharmaceuticals Canada Holdings, LP, an Ontario limited partnership Arena Pharmaceuticals Development GmbH, a limited liability company organized under the laws of Switzerland and having its domicile in Zug Arena Pharmaceuticals De

Form of Restricted Stock Unit Agreement for Employees (Post-Signing Grant)

Exhibit 10.59 ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant a Restricted Stock Unit Award (the ?Award?) under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) for the number of restricted stock units (the ?RSUs?) set forth below. This Award is subj

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 Arena Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-31161 23-2908305 (State or Other Jurisdiction of Incorporation) (Comm

Second Amended and Restated Severance Benefit Plan Eligibility Notice, dated as of December 12, 2021, by and between Arena and Amit D. Munshi

Exhibit 10.30 Second Amended and Restated Executive Officer Eligibility Notice Arena Pharmaceuticals, Inc. Second Amended and Restated Severance Benefit Plan Eligibility Notice To: Amit D. Munshi Date: December 12, 2021 Arena Pharmaceuticals, Inc. (the ?Company?) adopted the Arena Pharmaceuticals, Inc. Amended and Restated Severance Benefit Plan effective on June 11, 2021, as amended (the ?Plan?).

Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates –Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout

Exhibit 99.1 Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates –Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout PARK CITY, Utah, February 23, 2022 - Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021. Key Program & Cor

ARNA / Arena Pharmaceuticals, Inc. / Avoro Capital Advisors LLC - ARENA PHARMACEUTICALS, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Arena Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 040047607 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule p

ARNA / Arena Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Arena Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 040047607 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2022 Arena Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-31161 23-2908305 (State or other Jurisdiction of Incorporation) (Commi

ARNA / Arena Pharmaceuticals, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Arena Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 040047607 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2022 Arena Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-31161 23-2908305 (State or other Jurisdiction of Incorporation) (Commi

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant? ?? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Sta

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2022 (January 4, 2022)

DEFA14A 1 brhc10032664defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2022 (January 4, 2022) Arena Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-31161 23-29

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2022 (January 4, 2022) Arena Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-31161 23-2908305 (State or Other Jurisdiction of Inco

Schedule 14A

DEFM14A 1 ny20001688x2defm14a.htm DEFM14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant   ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

PREM14A 1 ny20001688x1prem14a.htm PREM 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant   ☐ Check the appropriate box: ☒ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant? ?? Check the appropriate box: ? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ?? Definitive Proxy S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant? ?? Check the appropriate box: ? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ?? Definitive Proxy S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2021 (December 12, 2021) Arena Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31161 23-2908305 (State or other jurisdiction of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant? ?? Check the appropriate box: ? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ?? Definitive Proxy S

AGREEMENT AND PLAN OF MERGER By and among PFIZER INC., ANTIOCH MERGER SUB, INC. and ARENA PHARMACEUTICALS, INC., Dated as of December 12, 2021

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER By and among PFIZER INC., ANTIOCH MERGER SUB, INC. and ARENA PHARMACEUTICALS, INC., Dated as of December 12, 2021 Table of Contents Page Number SECTION 1 - THE MERGER 1 1.1. The Merger 1 1.2. Effective Time 2 1.3. The Closing 2 1.4. Directors and Officers of the Surviving Corporation 2 1.5. Subsequent Actions 2 SECTION 2 - CONVERSION OF SECURITIES 3 2.1. Co

Agreement and Plan of Merger, dated as of December 12, 2021, by and among Arena Pharmaceuticals, Inc., Pfizer Inc. and Antioch Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 to Arena’s current report on Form 8-K, filed with the Securities and Exchange Commission on December 13, 2021, Commission File No. 000-31161)

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER By and among PFIZER INC., ANTIOCH MERGER SUB, INC. and ARENA PHARMACEUTICALS, INC., Dated as of December 12, 2021 Table of Contents Page Number SECTION 1 - THE MERGER 1 1.1. The Merger 1 1.2. Effective Time 2 1.3. The Closing 2 1.4. Directors and Officers of the Surviving Corporation 2 1.5. Subsequent Actions 2 SECTION 2 - CONVERSION OF SECURITIES 3 2.1. Co

Pfizer to Acquire Arena Pharmaceuticals Proposed acquisition offers potentially new, differentiated best-in-class approach to address unmet need for a broader number of patients with immuno-inflammatory diseases Expands innovative pipeline potentiall

Exhibit 99.1 For Immediate Release December 13, 2021 Pfizer Media Contact: +1 (212) 733-1226 [email protected] Pfizer Investor Contact: +1 (212) 733-4848 [email protected] Arena Pharmaceuticals, Inc. Investor & Media Contacts: Patrick Malloy Vice President, Investor Relations & Corporate Communications +1 (847) 987-4878 [email protected] Sara Doran Associate Director, Investor Relat

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2021 (December 12, 2021) Arena Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31161 23-2908305 (State or other jurisdiction of

Pfizer to Acquire Arena Pharmaceuticals Proposed acquisition offers potentially new, differentiated best-in-class approach to address unmet need for a broader number of patients with immuno-inflammatory diseases Expands innovative pipeline potentiall

Exhibit 99.1 For Immediate Release December 13, 2021 Pfizer Media Contact: +1 (212) 733-1226 [email protected] Pfizer Investor Contact: +1 (212) 733-4848 [email protected] Arena Pharmaceuticals, Inc. Investor & Media Contacts: Patrick Malloy Vice President, Investor Relations & Corporate Communications +1 (847) 987-4878 [email protected] Sara Doran Associate Director, Investor Relat

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 Arena Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-31161 23-2908305 (State or Other Jurisdiction of Incorporation) (Commi

Employment Agreement, dated as of

Exhibit 10.2 July 6, 2021 Dear Doug, Congratulations! I am very pleased to offer you a full-time position with Arena Pharmaceuticals, Inc. (?Arena?) as its Executive Vice President, Research & Development (?EVP, R&D?), based remotely in Milford, Pennsylvania. In this role, you will report to Amit Munshi, President and Chief Executive Officer and your start date will be July 19, 2021. This position

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

INDEX UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-31161 ARENA PHAR

Form of Performance Restricted Stock Unit Grant Agreement under the Arena Amended and Restated 2021 Long-Term Incentive Plan entered into by and between Arena and Douglas Manion

Exhibit 10.3 ARENA PHARMACEUTICALS, INC., 2021 LONG-TERM INCENTIVE PLAN PERFORMANCE RESTRICTED STOCK UNIT GRANT AGREEMENT This Grant Agreement (this ?Agreement?), effective as of August 15, 2021 (the ?Grant Date?), is entered into by and between Arena Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and (the ?Participant?) and evidences the terms of the Company?s grant to the Partici

Arena Reports Third Quarter Financial Results and Key Program Updates –Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout –First participant randomized in the Phase 2 trial for temanogrel in Raynaud’s phenomenon secondary to syst

Exhibit 99.1 Arena Reports Third Quarter Financial Results and Key Program Updates ?Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout ?First participant randomized in the Phase 2 trial for temanogrel in Raynaud?s phenomenon secondary to systemic sclerosis ?Strong liquidity position to support continued pipeline progress PARK CITY, Utah, November 4, 2021 - Arena Pharmaceutical

2021 Long-Term Incentive Plan, as amended as of

Exhibit 10.1 ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN Adopted by the Compensation Committee: April 19, 2021 Approved by the Stockholders: June 11, 2021 Amended and Restated by the Compensation Committee: October 5, 2021 1.General. (a)Successor to and Continuation of 2020 Plan. The Plan is the successor to and continuation of the 2020 Plan. As of the Effective Date: (i) no addition

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 Arena Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-31161 23-2908305 (State or Other Jurisdiction of Incorporation) (Commiss

Arena Reports Second Quarter Financial Results and Key Program Updates –Phase 3 ELEVATE UC 12 trial reached full enrollment; topline data expected Q1 2022 with ELEVATE UC 52 –Liquidity position at ~$1.0 billion as of June 30, 2021 to support continue

Exhibit 99.1 Arena Reports Second Quarter Financial Results and Key Program Updates ?Phase 3 ELEVATE UC 12 trial reached full enrollment; topline data expected Q1 2022 with ELEVATE UC 52 ?Liquidity position at ~$1.0 billion as of June 30, 2021 to support continued pipeline progress PARK CITY, Utah, August 5, 2021 - Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and re

Amended and Restated Severance Benefit Plan Eligibility Notice, dated as of June 1

Arena Pharmaceuticals, Inc. Amended and Restated Severance Benefit Plan Eligibility Notice To: Amit D. Munshi Date: June 11, 2021 Arena Pharmaceuticals, Inc. (the ?Company?) adopted the Arena Pharmaceuticals, Inc. Amended and Restated Severance Benefit Plan effective on June 11, 2021 (the ?Plan?). Capitalized terms used in this Eligibility Notice have the meanings set forth in the Plan. The Compan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

INDEX UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-31161 ARENA PHARMACEU

Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan, as amended as of July 1

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN Adopted by the Compensation Committee: April 19, 2021 Approved by the Stockholders: June 11, 2021 Amended and Restated by the Compensation Committee: July 16, 2021 1.General. (a)Successor to and Continuation of 2020 Plan. The Plan is the successor to and continuation of the 2020 Plan. As of the Effective Date: (i) no additional awards may b

ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED SEVERANCE BENEFIT PLAN

Exhibit 99.3 ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED SEVERANCE BENEFIT PLAN Introduction. The Arena Pharmaceuticals, Inc. Amended and Restated Severance Benefit Plan originally effective on January 20, 2006 and amended and restated on May 9, 2016 and further amended on June 15, 2016, August 15, 2016, March 20, 2017, October 31, 2018, November 26, 2018 and January 4, 2019 (collectively, th

Arena Pharmaceuticals, Inc. Non-Employee Director Compensation

Approved June 11, 2021 Exhibit 99.1 Arena Pharmaceuticals, Inc. Non-Employee Director Compensation Equity Awards ?Annual Equity Awards for continuing directors and new directors: Stock Options: Continuing and new directors elected at our annual stockholders? meeting will be granted $200,000 of economic value in the form of non-qualified stock options to purchase shares of our common stock. The num

Description of the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (“2021 Plan”)

Exhibit 99.2 Description of the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (?2021 Plan?) The following summary describes the principal features of the 2021 Plan and is qualified in its entirety by reference to the full text of the 2021 Plan. A copy of the 2021 Plan is filed as Appendix A to the proxy statement for our 2021 Annual Meeting filed with the SEC. Purpose The 2021 Plan is

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2021 Arena Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-31161 23-2908305 (State or Other Jurisdiction of Incorporation) (Commissi

Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the ?Company?), a Delaware corporation, hereby adopts the following Amended and Restated 2020 Long-Term Incentive Plan which amends and restates the terms of the Company?s 2020 Long-Term Incentive Plan that was previously in effect (the ?Plan?) effective as of the Effective Date set forth in

Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the ?Company?), a Delaware corporation, hereby adopts the following Amended and Restated 2020 Long-Term Incentive Plan which amends and restates the terms of the Company?s 2020 Long-Term Incentive Plan that was previously in effect (the ?Plan?) effective as of the Effective Date set forth in

Form of Nonqualified Stock Option Grant Agreement for Employees and Consultants under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN OPTION GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant an Option under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) to purchase the number of shares of Common Stock (the ?Shares?) set forth below at the exercise price set forth below. This Option is subject to all of the te

As filed with the Securities and Exchange Commission on June 11, 2021

As filed with the Securities and Exchange Commission on June 11, 2021 Registration No.

As filed with the Securities and Exchange Commission on June 11, 2021

As filed with the Securities and Exchange Commission on June 11, 2021 Registration No.

Form of Restricted Stock Unit Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant a Restricted Stock Unit Award (the ?Award?) under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) for the number of restricted stock units (the ?RSUs?) set forth below. This Award is subject to all of

Form of Restricted Stock Unit Grant Agreement under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant a Restricted Stock Unit Award (the ?Award?) under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) for the number of restricted stock units (the ?RSUs?) set forth below. This Award is subject to all of

Form of Nonqualified Stock Option Grant Agreement for Employees and Consultants under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN OPTION GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant an Option under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) to purchase the number of shares of Common Stock (the ?Shares?) set forth below at the exercise price set forth below. This Option is subject to all of the te

Form of Nonqualified Stock Option Grant Agreement for Employees and Consultants under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN OPTION GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant an Option under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) to purchase the number of shares of Common Stock (the ?Shares?) set forth below at the exercise price set forth below. This Option is subject to all of the te

Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the ?Company?), a Delaware corporation, hereby adopts the following Amended and Restated 2020 Long-Term Incentive Plan which amends and restates the terms of the Company?s 2020 Long-Term Incentive Plan that was previously in effect (the ?Plan?) effective as of the Effective Date set forth in

Form of Nonqualified Stock Option Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN OPTION GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant an Option under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) to purchase the number of shares of Common Stock (the ?Shares?) set forth below at the exercise price set forth below. This Option is subject to all of the te

As filed with the Securities and Exchange Commission on June 11, 2021

As filed with the Securities and Exchange Commission on June 11, 2021 Registration No.

Form of Restricted Stock Unit Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant a Restricted Stock Unit Award (the ?Award?) under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) for the number of restricted stock units (the ?RSUs?) set forth below. This Award is subject to all of

Form of Restricted Stock Unit Grant Agreement under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant a Restricted Stock Unit Award (the ?Award?) under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) for the number of restricted stock units (the ?RSUs?) set forth below. This Award is subject to all of

Form of Restricted Stock Unit Grant Agreement under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant a Restricted Stock Unit Award (the ?Award?) under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) for the number of restricted stock units (the ?RSUs?) set forth below. This Award is subject to all of

Form of Nonqualified Stock Option Grant Agreement for Employees and Consultants under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN OPTION GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant an Option under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) to purchase the number of shares of Common Stock (the ?Shares?) set forth below at the exercise price set forth below. This Option is subject to all of the te

Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN ADOPTED BY THE COMPENSATION COMMITTEE: APRIL 19, 2021 APPROVED BY THE STOCKHOLDERS: JUNE 11, 2021 1.?GENERAL. (a)?Successor to and Continuation of 2020 Plan. The Plan is the successor to and continuation of the 2020 Plan. As of the Effective Date: (i) no additional awards may be granted under the 2020 Plan or any other Prior Plan; (ii) the

Form of Nonqualified Stock Option Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN OPTION GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant an Option under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) to purchase the number of shares of Common Stock (the ?Shares?) set forth below at the exercise price set forth below. This Option is subject to all of the te

Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the ?Company?), a Delaware corporation, hereby adopts the following Amended and Restated 2020 Long-Term Incentive Plan which amends and restates the terms of the Company?s 2020 Long-Term Incentive Plan that was previously in effect (the ?Plan?) effective as of the Effective Date set forth in

Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN ADOPTED BY THE COMPENSATION COMMITTEE: APRIL 19, 2021 APPROVED BY THE STOCKHOLDERS: JUNE 11, 2021 1.?GENERAL. (a)?Successor to and Continuation of 2020 Plan. The Plan is the successor to and continuation of the 2020 Plan. As of the Effective Date: (i) no additional awards may be granted under the 2020 Plan or any other Prior Plan; (ii) the

Form of Nonqualified Stock Option Grant Agreement for Employees and Consultants under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN OPTION GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant an Option under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) to purchase the number of shares of Common Stock (the ?Shares?) set forth below at the exercise price set forth below. This Option is subject to all of the te

Form of Restricted Stock Unit Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant a Restricted Stock Unit Award (the ?Award?) under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) for the number of restricted stock units (the ?RSUs?) set forth below. This Award is subject to all of

Form of Restricted Stock Unit Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant a Restricted Stock Unit Award (the ?Award?) under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) for the number of restricted stock units (the ?RSUs?) set forth below. This Award is subject to all of

As filed with the Securities and Exchange Commission on June 11, 2021

As filed with the Securities and Exchange Commission on June 11, 2021 Registration No.

Form of Restricted Stock Unit Grant Agreement under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant a Restricted Stock Unit Award (the ?Award?) under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) for the number of restricted stock units (the ?RSUs?) set forth below. This Award is subject to all of

Form of Nonqualified Stock Option Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN OPTION GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant an Option under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) to purchase the number of shares of Common Stock (the ?Shares?) set forth below at the exercise price set forth below. This Option is subject to all of the te

Form of Nonqualified Stock Option Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN OPTION GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant an Option under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) to purchase the number of shares of Common Stock (the ?Shares?) set forth below at the exercise price set forth below. This Option is subject to all of the te

Form of Nonqualified Stock Option Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN OPTION GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant an Option under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) to purchase the number of shares of Common Stock (the ?Shares?) set forth below at the exercise price set forth below. This Option is subject to all of the te

Form of Nonqualified Stock Option Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN OPTION GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant an Option under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) to purchase the number of shares of Common Stock (the ?Shares?) set forth below at the exercise price set forth below. This Option is subject to all of the te

Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN ADOPTED BY THE COMPENSATION COMMITTEE: APRIL 19, 2021 APPROVED BY THE STOCKHOLDERS: JUNE 11, 2021 1.?GENERAL. (a)?Successor to and Continuation of 2020 Plan. The Plan is the successor to and continuation of the 2020 Plan. As of the Effective Date: (i) no additional awards may be granted under the 2020 Plan or any other Prior Plan; (ii) the

Form of Nonqualified Stock Option Grant Agreement for Employees and Consultants under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN OPTION GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant an Option under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) to purchase the number of shares of Common Stock (the ?Shares?) set forth below at the exercise price set forth below. This Option is subject to all of the te

Form of Restricted Stock Unit Grant Agreement under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant a Restricted Stock Unit Award (the ?Award?) under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) for the number of restricted stock units (the ?RSUs?) set forth below. This Award is subject to all of

Form of Restricted Stock Unit Grant Agreement under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant a Restricted Stock Unit Award (the ?Award?) under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) for the number of restricted stock units (the ?RSUs?) set forth below. This Award is subject to all of

Form of Restricted Stock Unit Grant Agreement under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant a Restricted Stock Unit Award (the ?Award?) under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) for the number of restricted stock units (the ?RSUs?) set forth below. This Award is subject to all of

Form of Restricted Stock Unit Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant a Restricted Stock Unit Award (the ?Award?) under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) for the number of restricted stock units (the ?RSUs?) set forth below. This Award is subject to all of

As filed with the Securities and Exchange Commission on June 11, 2021

As filed with the Securities and Exchange Commission on June 11, 2021 Registration No.

As filed with the Securities and Exchange Commission on June 11, 2021

As filed with the Securities and Exchange Commission on June 11, 2021 Registration No.

As filed with the Securities and Exchange Commission on June 11, 2021

As filed with the Securities and Exchange Commission on June 11, 2021 Registration No.

As filed with the Securities and Exchange Commission on June 11, 2021

As filed with the Securities and Exchange Commission on June 11, 2021 Registration No.

Form of Restricted Stock Unit Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant a Restricted Stock Unit Award (the ?Award?) under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) for the number of restricted stock units (the ?RSUs?) set forth below. This Award is subject to all of

Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN ADOPTED BY THE COMPENSATION COMMITTEE: APRIL 19, 2021 APPROVED BY THE STOCKHOLDERS: JUNE 11, 2021 1.?GENERAL. (a)?Successor to and Continuation of 2020 Plan. The Plan is the successor to and continuation of the 2020 Plan. As of the Effective Date: (i) no additional awards may be granted under the 2020 Plan or any other Prior Plan; (ii) the

Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the ?Company?), a Delaware corporation, hereby adopts the following Amended and Restated 2020 Long-Term Incentive Plan which amends and restates the terms of the Company?s 2020 Long-Term Incentive Plan that was previously in effect (the ?Plan?) effective as of the Effective Date set forth in

Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the ?Company?), a Delaware corporation, hereby adopts the following Amended and Restated 2020 Long-Term Incentive Plan which amends and restates the terms of the Company?s 2020 Long-Term Incentive Plan that was previously in effect (the ?Plan?) effective as of the Effective Date set forth in

Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the ?Company?), a Delaware corporation, hereby adopts the following Amended and Restated 2020 Long-Term Incentive Plan which amends and restates the terms of the Company?s 2020 Long-Term Incentive Plan that was previously in effect (the ?Plan?) effective as of the Effective Date set forth in

Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the ?Company?), a Delaware corporation, hereby adopts the following Amended and Restated 2020 Long-Term Incentive Plan which amends and restates the terms of the Company?s 2020 Long-Term Incentive Plan that was previously in effect (the ?Plan?) effective as of the Effective Date set forth in

Form of Restricted Stock Unit Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant a Restricted Stock Unit Award (the ?Award?) under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) for the number of restricted stock units (the ?RSUs?) set forth below. This Award is subject to all of

Form of Restricted Stock Unit Grant Agreement under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant a Restricted Stock Unit Award (the ?Award?) under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) for the number of restricted stock units (the ?RSUs?) set forth below. This Award is subject to all of

Form of Nonqualified Stock Option Grant Agreement for Employees and Consultants under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN OPTION GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant an Option under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) to purchase the number of shares of Common Stock (the ?Shares?) set forth below at the exercise price set forth below. This Option is subject to all of the te

Form of Nonqualified Stock Option Grant Agreement for Employees and Consultants under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN OPTION GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant an Option under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) to purchase the number of shares of Common Stock (the ?Shares?) set forth below at the exercise price set forth below. This Option is subject to all of the te

Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN ADOPTED BY THE COMPENSATION COMMITTEE: APRIL 19, 2021 APPROVED BY THE STOCKHOLDERS: JUNE 11, 2021 1.?GENERAL. (a)?Successor to and Continuation of 2020 Plan. The Plan is the successor to and continuation of the 2020 Plan. As of the Effective Date: (i) no additional awards may be granted under the 2020 Plan or any other Prior Plan; (ii) the

Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN ADOPTED BY THE COMPENSATION COMMITTEE: APRIL 19, 2021 APPROVED BY THE STOCKHOLDERS: JUNE 11, 2021 1.?GENERAL. (a)?Successor to and Continuation of 2020 Plan. The Plan is the successor to and continuation of the 2020 Plan. As of the Effective Date: (i) no additional awards may be granted under the 2020 Plan or any other Prior Plan; (ii) the

Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN ADOPTED BY THE COMPENSATION COMMITTEE: APRIL 19, 2021 APPROVED BY THE STOCKHOLDERS: JUNE 11, 2021 1.?GENERAL. (a)?Successor to and Continuation of 2020 Plan. The Plan is the successor to and continuation of the 2020 Plan. As of the Effective Date: (i) no additional awards may be granted under the 2020 Plan or any other Prior Plan; (ii) the

Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN ADOPTED BY THE COMPENSATION COMMITTEE: APRIL 19, 2021 APPROVED BY THE STOCKHOLDERS: JUNE 11, 2021 1.?GENERAL. (a)?Successor to and Continuation of 2020 Plan. The Plan is the successor to and continuation of the 2020 Plan. As of the Effective Date: (i) no additional awards may be granted under the 2020 Plan or any other Prior Plan; (ii) the

As filed with the Securities and Exchange Commission on June 11, 2021

As filed with the Securities and Exchange Commission on June 11, 2021 Registration No.

As filed with the Securities and Exchange Commission on June 11, 2021

As filed with the Securities and Exchange Commission on June 11, 2021 Registration No.

Form of Restricted Stock Unit Grant Agreement under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant a Restricted Stock Unit Award (the ?Award?) under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) for the number of restricted stock units (the ?RSUs?) set forth below. This Award is subject to all of

Form of Restricted Stock Unit Grant Agreement under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant a Restricted Stock Unit Award (the ?Award?) under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) for the number of restricted stock units (the ?RSUs?) set forth below. This Award is subject to all of

Form of Nonqualified Stock Option Grant Agreement for Employees and Consultants under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN OPTION GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant an Option under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) to purchase the number of shares of Common Stock (the ?Shares?) set forth below at the exercise price set forth below. This Option is subject to all of the te

Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the ?Company?), a Delaware corporation, hereby adopts the following Amended and Restated 2020 Long-Term Incentive Plan which amends and restates the terms of the Company?s 2020 Long-Term Incentive Plan that was previously in effect (the ?Plan?) effective as of the Effective Date set forth in

Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the ?Company?), a Delaware corporation, hereby adopts the following Amended and Restated 2020 Long-Term Incentive Plan which amends and restates the terms of the Company?s 2020 Long-Term Incentive Plan that was previously in effect (the ?Plan?) effective as of the Effective Date set forth in

Form of Nonqualified Stock Option Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN OPTION GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant an Option under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) to purchase the number of shares of Common Stock (the ?Shares?) set forth below at the exercise price set forth below. This Option is subject to all of the te

Form of Nonqualified Stock Option Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN OPTION GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant an Option under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) to purchase the number of shares of Common Stock (the ?Shares?) set forth below at the exercise price set forth below. This Option is subject to all of the te

Form of Nonqualified Stock Option Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN OPTION GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant an Option under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) to purchase the number of shares of Common Stock (the ?Shares?) set forth below at the exercise price set forth below. This Option is subject to all of the te

Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN ADOPTED BY THE COMPENSATION COMMITTEE: APRIL 19, 2021 APPROVED BY THE STOCKHOLDERS: JUNE 11, 2021 1.?GENERAL. (a)?Successor to and Continuation of 2020 Plan. The Plan is the successor to and continuation of the 2020 Plan. As of the Effective Date: (i) no additional awards may be granted under the 2020 Plan or any other Prior Plan; (ii) the

Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN ADOPTED BY THE COMPENSATION COMMITTEE: APRIL 19, 2021 APPROVED BY THE STOCKHOLDERS: JUNE 11, 2021 1.?GENERAL. (a)?Successor to and Continuation of 2020 Plan. The Plan is the successor to and continuation of the 2020 Plan. As of the Effective Date: (i) no additional awards may be granted under the 2020 Plan or any other Prior Plan; (ii) the

Form of Nonqualified Stock Option Grant Agreement for Employees and Consultants under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN OPTION GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant an Option under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) to purchase the number of shares of Common Stock (the ?Shares?) set forth below at the exercise price set forth below. This Option is subject to all of the te

Form of Restricted Stock Unit Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant a Restricted Stock Unit Award (the ?Award?) under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) for the number of restricted stock units (the ?RSUs?) set forth below. This Award is subject to all of

Form of Restricted Stock Unit Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant a Restricted Stock Unit Award (the ?Award?) under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) for the number of restricted stock units (the ?RSUs?) set forth below. This Award is subject to all of

Form of Restricted Stock Unit Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant a Restricted Stock Unit Award (the ?Award?) under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) for the number of restricted stock units (the ?RSUs?) set forth below. This Award is subject to all of

Form of Nonqualified Stock Option Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN OPTION GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant an Option under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) to purchase the number of shares of Common Stock (the ?Shares?) set forth below at the exercise price set forth below. This Option is subject to all of the te

Form of Restricted Stock Unit Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant a Restricted Stock Unit Award (the ?Award?) under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) for the number of restricted stock units (the ?RSUs?) set forth below. This Award is subject to all of

Form of Restricted Stock Unit Grant Agreement under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant a Restricted Stock Unit Award (the ?Award?) under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) for the number of restricted stock units (the ?RSUs?) set forth below. This Award is subject to all of

As filed with the Securities and Exchange Commission on June 11, 2021

As filed with the Securities and Exchange Commission on June 11, 2021 Registration No.

Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN ADOPTED BY THE COMPENSATION COMMITTEE: APRIL 19, 2021 APPROVED BY THE STOCKHOLDERS: JUNE 11, 2021 1.?GENERAL. (a)?Successor to and Continuation of 2020 Plan. The Plan is the successor to and continuation of the 2020 Plan. As of the Effective Date: (i) no additional awards may be granted under the 2020 Plan or any other Prior Plan; (ii) the

Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the ?Company?), a Delaware corporation, hereby adopts the following Amended and Restated 2020 Long-Term Incentive Plan which amends and restates the terms of the Company?s 2020 Long-Term Incentive Plan that was previously in effect (the ?Plan?) effective as of the Effective Date set forth in

Form of Nonqualified Stock Option Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc.

ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN OPTION GRANT NOTICE Arena Pharmaceuticals, Inc. (the ?Company?) hereby grants to Participant an Option under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the ?Plan?) to purchase the number of shares of Common Stock (the ?Shares?) set forth below at the exercise price set forth below. This Option is subject to all of the te

Form of Nonqualified Stock Option Grant Agreement for Employees and Consultants under the Arena Pharmaceuticals, Inc.

EX-99.3 6 formofnonqualifiedstockopt.htm EX-99.3 ARENA PHARMACEUTICALS, INC. 2021 LONG-TERM INCENTIVE PLAN OPTION GRANT NOTICE Arena Pharmaceuticals, Inc. (the “Company”) hereby grants to Participant an Option under the Arena Pharmaceuticals, Inc. 2021 Long-Term Incentive Plan (the “Plan”) to purchase the number of shares of Common Stock (the “Shares”) set forth below at the exercise price set for

Quarterly Report - 10-Q

INDEX UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-31161 ARENA PHARMACE

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 Arena Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-31161 23-2908305 (State or Other Jurisdiction of Incorporation) (Commission

Arena’s Amended and Restated 2020 Long-Term Incentive Plan, amended as of April 13, 2021

ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the ?Company?), a Delaware corporation, hereby adopts the following Amended and Restated 2020 Long-Term Incentive Plan which amends and restates the terms of the Company?s 2020 Long-Term Incentive Plan that was previously in effect (the ?Plan?) effective as of the Effective Date set forth in

Arena Reports First Quarter Financial Results with Strong Cash Position and Continued Progress on Pipeline Over the Quarter

Exhibit 99.1 Arena Reports First Quarter Financial Results with Strong Cash Position and Continued Progress on Pipeline Over the Quarter ?Liquidity position at $1.1 billion as of March 31, 2021 to support continued pipeline progress SAN DIEGO, Calif., May 5, 2021 - Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the first quarter ende

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e

Definitive Proxy Statement on Schedule 14A

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2021 Arena Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-31161 23-2908305 (State or Other Jurisdiction of Incorporation) (Commissi

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-31161 ARENA PHARMACEUTICALS, INC

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of Arena Pharmaceuticals, Inc. As of December 31, 2020 125 Royalty Inc., a Delaware corporation 356 Royalty Inc., a Delaware corporation Arena Pharmaceuticals Canada Holdings, LP, an Ontario limited partnership Arena Pharmaceuticals Development GmbH, a limited liability company organized under the laws of Switzerland and having its domicile in Zug Arena Pharmaceuticals De

Arena Reports Fourth Quarter Financial Results with Strong Liquidity Position and Maintained Pipeline Progress Over the Quarter - Significant pipeline progress with potentially first- or best-in-class drug candidates - Strong cash position of $1.1bil

Exhibit 99.1 Arena Reports Fourth Quarter Financial Results with Strong Liquidity Position and Maintained Pipeline Progress Over the Quarter - Significant pipeline progress with potentially first- or best-in-class drug candidates - Strong cash position of $1.1billion as of December 31, 2020 February 23, 2021 - Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reporte

Form of Performance Restricted Stock Unit Grant Agreement under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

Exhibit 10.50 Arena Pharmaceuticals, Inc., 2020 Long-Term Incentive Plan Performance Restricted Stock Unit Grant Agreement This Grant Agreement (this ?Agreement?), effective as of (the ?Grant Date?), is entered into by and between Arena Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and (the ?Participant?) and evidences the terms of the Company?s grant to the Participant of a perfo

Consulting Services Agreement, dated March 2, 2020, by and between Arena and Steven W. Spector

Exhibit 10.12 CONSULTING SERVICES AGREEMENT THIS CONSULTING SERVICES AGREEMENT (the ?Agreement?) is entered into as of March 2, 2020 (?Effective Date?) by and between Arena Pharmaceuticals, Inc., a Delaware corporation (?Arena?), and Steven Spector (?Consultant?). WHEREAS, Arena wishes to obtain the services of Consultant for certain purposes and Consultant wishes to provide such services, all sub

Financial Statements and Exhibits, Results of Operations and Financial Condition

e UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2021 Arena Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-31161 23-2908305 (State or Other Jurisdiction of Incorporation) (Co

(incorporated by reference to Exhibit 10.1 to Arena’s annual report on Form 10-K, filed with the Securities and Exchange Commission on February 23, 2021, Commission File No. 000-31161)

Exhibit 10.1 INDEMNIFICATION AGREEMENT (Director) This Indemnification Agreement (?Agreement?) is made as of by and between Arena Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and (?Indemnitee?). RECITALS WHEREAS, Indemnitee is currently serving as a director of the Company; WHEREAS, Article V of the Fifth Amended and Restated Certificate of Incorporation of the Company (the ?Cert

Arena’s Amended and Restated 2020 Long-Term Incentive Plan, amended as of February 12, 2021

Exhibit 10.45 ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the ?Company?), a Delaware corporation, hereby adopts the following Amended and Restated 2020 Long-Term Incentive Plan which amends and restates the terms of the Company?s 2020 Long-Term Incentive Plan that was previously in effect (the ?Plan?) effective as of the Effective Dat

(incorporated by reference to Exhibit 10.2 to Arena’s annual report on Form 10-K, filed with the Securities and Exchange Commission on February 23, 2021, Commission File No. 000-31161)

Exhibit 10.2 INDEMNIFICATION AGREEMENT (Officer) This Indemnification Agreement (?Agreement?) is made as of by and between Arena Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and (?Indemnitee?). RECITALS WHEREAS, Indemnitee is currently serving as an officer of the Company; WHEREAS, Article V of the Fifth Amended and Restated Certificate of Incorporation of the Company (the ?Certi

Separation Agreement, dated as of October 27, 2020, by and between Arena and Kevin R. Lind

Exhibit 10.22 Arena Pharmaceuticals, Inc. October 27, 2020 Mr. Kevin Lind Re: Separation Agreement Dear Kevin, This letter shall constitute the Separation Agreement (the ?Agreement?) between you and Arena Pharmaceuticals, Inc. (the ?Company?). 1.Separation Date; Accrued Salary and Paid Time Off. Your employment with the Company will end on October 27, 2020, which will become your employment separa

Transition and Retirement Agreement, dated January 13, 2020, by and between Arena and Steven W. Spector

Exhibit 10.11 Arena Pharmaceuticals, Inc. January 13, 2020 Steven Spector Re: Transition and Retirement Agreement Dear Steven, This letter shall constitute the Transition and Retirement Agreement (the ?Agreement?) between you and Arena Pharmaceuticals, Inc. (the ?Company?). 1.Retirement Date. Your employment with the Company will continue through March 1, 2020, which will become your employment te

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2021 Arena Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-31161 23-2908305 (State or Other Jurisdiction of Incorporation) (Comm

Arena Pharmaceuticals, Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Arena Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 040047607 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule purs

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Arena Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 040047607 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is f

SCHEDULE 13G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Arena Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 040047607 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 Arena Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-31161 23-2908305 (State or Other Jurisdiction of Incorporation) (Commi

Forward Looking Statements This presentation includes forward-looking statements that involve a number of risks and uncertainties, including statements about catalysts, value, our investigative stage drug candidates, including with respect to their p

JANUARY 2021 • NASDAQ: ARNA Exhibit 99.1 Forward Looking Statements This presentation includes forward-looking statements that involve a number of risks and uncertainties, including statements about catalysts, value, our investigative stage drug candidates, including with respect to their potential (including to become first or best-in-class), safety, efficacy, indications, significance of data, d

Forward Looking Statements This presentation includes forward-looking statements that involve a number of risks and uncertainties, including statements about the Arena investment thesis, catalysts, value, our investigative stage drug candidates, incl

November 2020 • Nasdaq: ARNA Exhibit 99.1 Forward Looking Statements This presentation includes forward-looking statements that involve a number of risks and uncertainties, including statements about the Arena investment thesis, catalysts, value, our investigative stage drug candidates, including with respect to their potential (including to become first or best-in-class), safety, efficacy, indica

Regulation FD Disclosure, Financial Statements and Exhibits - 8-K - NOVEMBER 2020 CORPORATE PRESENTATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2020 Arena Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-31161 23-2908305 (State or Other Jurisdiction of Incorporation) (Comm

Arena’s Amended and Restated 2020 Long-Term Incentive Plan, amended as of October 14, 2020

Exhibit 10.1 ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the ?Company?), a Delaware corporation, hereby adopts the following Amended and Restated 2020 Long-Term Incentive Plan which amends and restates the terms of the Company?s 2020 Long-Term Incentive Plan that was previously in effect (the ?Plan?) effective as of the Effective Date

Arena Reports Third Quarter Financial Results with Strong Cash Position, Advancing Etrasimod Into a Phase 3 Registrational Program in Atopic Dermatitis

EX-99.1 2 arna-ex9916.htm EX-99.1 Exhibit 99.1 Arena Reports Third Quarter Financial Results with Strong Cash Position, Advancing Etrasimod Into a Phase 3 Registrational Program in Atopic Dermatitis - Delivered compelling topline results from ADVISE Ph 2b trial evaluating etrasimod in atopic dermatitis; advancing into a Ph 3 registrational program - Initiated etrasimod trials: ELEVATE UC 12 Ph 3,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-31161 ARENA PHARMACEUT

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

e UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 Arena Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-31161 23-2908305 (State or Other Jurisdiction of Incorporation) (Com

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events - 8-K - LONGBOARD PHARMACEUTICALS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2020 Arena Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-31161 23-2908305 (State or Other Jurisdiction of Incorporation) (Commi

Regulation FD Disclosure, Financial Statements and Exhibits - 8-K ATOPIC DERMATITIS OVERVIEW

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2020 Arena Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-31161 23-2908305 (State or Other Jurisdiction of Incorporation) (Commi

Forward Looking Statements This presentation includes forward-looking statements that involve a number of risks and uncertainties, including statements about our investigative-stage drug candidate etrasimod, including with respect to its potential (i

Nasdaq: ARNA • October 2020 Atopic Dermatitis Overview Exhibit 99.1 Forward Looking Statements This presentation includes forward-looking statements that involve a number of risks and uncertainties, including statements about our investigative-stage drug candidate etrasimod, including with respect to its potential (including to become first- or best-in-class), safety, efficacy, indications, mechan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2020 Arena Pharmace

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2020 Arena Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-31161 23-2908305 (State or Other Jurisdiction of Incorporation) (Com

Forward Looking Statements September 2020 • This presentation includes forward-looking statements that involve a number of risks and uncertainties, including statements about Arena’s business, catalysts, value, our investigative stage drug candidates

September 2020 Etrasimod IBD Program Update Exhibit 99.1 Forward Looking Statements September 2020 • This presentation includes forward-looking statements that involve a number of risks and uncertainties, including statements about Arena’s business, catalysts, value, our investigative stage drug candidates, including with respect to their potential (including to become first or best-in-class), saf

Arena Reports Second Quarter Financial Results with Strong Liquidity Position, and Maintained Pipeline Progress Over the Quarter

Exhibit 99.1 Arena Reports Second Quarter Financial Results with Strong Liquidity Position, and Maintained Pipeline Progress Over the Quarter - Phase 2b ADVISE trial evaluating etrasimod in atopic dermatitis (AD) enrollment complete, topline data expected Q4 2020 - Progressing first- or best-in-class drug candidates with liquidity position of ~$1.3bn as of June 30, 2020 SAN DIEGO, Calif., August 5

Services Agreement, dated as of June 9, 2020, by and between Arena and Preston Klassen

Exhibit 10.8 SERVICES AGREEMENT THIS SERVICES AGREEMENT (the “Agreement”) is entered into as of June 9, 2020 (“Effective Date”) by and between Arena Pharmaceuticals, Inc., a Delaware corporation (“Arena”), and Preston Klassen, M.D., M.H.S. (“Consultant”). WHEREAS, Arena wishes to obtain the services of Consultant for certain purposes and Consultant wishes to provide such services, all subject to t

Arena’s Amended and Restated 2017 Long-Term Incentive Plan, as amended as of May 14, 2020

Exhibit 10.2 ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2017 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, hereby adopts the following Amended and Restated 2017 Long-Term Incentive Plan (the “Restatement”) which amends and restates the terms of the Company’s Amended and Restated 2017 Long-Term Incentive Plan that was previously in effect (the “

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-31161 ARENA PHARMACEUTICALS

Financial Statements and Exhibits, Results of Operations and Financial Condition

e UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2020 Arena Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-31161 23-2908305 (State or Other Jurisdiction of Incorporation) (Commi

Summary of compensation for Arena's non-employee directors, approved June 12, 2020

Exhibit 10.1 Approved June 12, 2020 Arena Pharmaceuticals, Inc. Non-Employee Director Compensation Equity • Annual Award for Continuing directors and new directors: Options: Continuing and new directors elected at our annual stockholders’ meeting will be granted non-qualified stock options to purchase 5,000 shares of our common stock. The options are granted effective on the date of our annual sto

Arena’s Amended and Restated 2020 Long-Term Incentive Plan, amended as of July 13, 2020

Exhibit 10.3 ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, hereby adopts the following Amended and Restated 2020 Long-Term Incentive Plan which amends and restates the terms of the Company’s 2020 Long-Term Incentive Plan that was previously in effect (the “Plan”) effective as of the Effective Date

Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

EX-99.5 5 arna-ex99510.htm ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Exhibit 99.5 ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, hereby adopts the following Amended and Restated 2020 Long-Term Incentive Plan which amends and restates the terms of the Company’s 2

- S-8 POS - REGISTRATION NO. 333-232142

As filed with the Securities and Exchange Commission on June 19, 2020 Registration No.

- S-8 POS REGISTRATION NO. 333-214529

As filed with the Securities and Exchange Commission on June 19, 2020 Registration No.

Form of Nonqualified Stock Option Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

. Exhibit 99.9 Arena Pharmaceuticals, Inc. 2020 Long-Term Incentive Plan Nonqualified Stock Option Grant Agreement for Non-Employee Directors THIS GRANT AGREEMENT (this “Agreement”), effective as of (the “Grant Date”), is entered into by and between Arena Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (the “Participant”). 1.Grant of Options. The Company hereby grants to the Par

Form of Restricted Stock Unit Grant Agreement under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

Exhibit 99.7 Arena Pharmaceuticals, Inc., 2020 Long-Term Incentive Plan Restricted Stock Unit Grant Agreement This Grant Agreement (this “Agreement”), effective as of (the “Grant Date”), is entered into by and between Arena Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (the “Participant”). 1.Grant of Restricted Stock Units. The Company hereby grants to the Participant Restrict

Form of Restricted Stock Unit Grant Agreement under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

Exhibit 99.7 Arena Pharmaceuticals, Inc., 2020 Long-Term Incentive Plan Restricted Stock Unit Grant Agreement This Grant Agreement (this “Agreement”), effective as of (the “Grant Date”), is entered into by and between Arena Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (the “Participant”). 1.Grant of Restricted Stock Units. The Company hereby grants to the Participant Restrict

Form of Nonqualified Stock Option Grant Agreement for Employees and Consultants under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

Exhibit 99.6 Arena Pharmaceuticals, Inc., 2020 Long-Term Incentive Plan Nonqualified Stock Option Grant Agreement for Employees and Consultants This Grant Agreement (this “Agreement”), effective as of (the “Grant Date”), is entered into by and between Arena Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (the “Participant”). 1.Grant of Options. The Company hereby grants to the P

Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

Exhibit 99.5 ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, hereby adopts the following Amended and Restated 2020 Long-Term Incentive Plan which amends and restates the terms of the Company’s 2020 Long-Term Incentive Plan that was previously in effect (the “Plan”) effective as of the Effective Date

Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

Exhibit 99.5 ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, hereby adopts the following Amended and Restated 2020 Long-Term Incentive Plan which amends and restates the terms of the Company’s 2020 Long-Term Incentive Plan that was previously in effect (the “Plan”) effective as of the Effective Date

Arena Pharmaceuticals, Inc. Amended and Restated 2017 Long-Term Incentive Plan

EX-99.4 4 arna-ex99410.htm ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2017 LONG-TERM INCENTIVE PLAN . Exhibit 99.4 ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2017 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, hereby adopts the following Amended and Restated 2017 Long-Term Incentive Plan (the “Restatement”) which amends and restates the te

Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

Exhibit 99.5 ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, hereby adopts the following Amended and Restated 2020 Long-Term Incentive Plan which amends and restates the terms of the Company’s 2020 Long-Term Incentive Plan that was previously in effect (the “Plan”) effective as of the Effective Date

Form of Nonqualified Stock Option Grant Agreement for Employees and Consultants under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

Exhibit 99.6 Arena Pharmaceuticals, Inc., 2020 Long-Term Incentive Plan Nonqualified Stock Option Grant Agreement for Employees and Consultants This Grant Agreement (this “Agreement”), effective as of (the “Grant Date”), is entered into by and between Arena Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (the “Participant”). 1.Grant of Options. The Company hereby grants to the P

Form of Restricted Stock Unit Grant Agreement under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

EX-99.7 7 arna-ex9978.htm FORM OF RESTRICTED STOCK UNIT GRANT AGREEMENT UNDER THE ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Exhibit 99.7 Arena Pharmaceuticals, Inc., 2020 Long-Term Incentive Plan Restricted Stock Unit Grant Agreement This Grant Agreement (this “Agreement”), effective as of (the “Grant Date”), is entered into by and between Arena Pharmaceuticals

Form of Nonqualified Stock Option Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

EX-99.9 9 arna-ex99913.htm FORM OF NONQUALIFIED STOCK OPTION GRANT AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN . Exhibit 99.9 Arena Pharmaceuticals, Inc. 2020 Long-Term Incentive Plan Nonqualified Stock Option Grant Agreement for Non-Employee Directors THIS GRANT AGREEMENT (this “Agreement”), effective as of (the “Gr

Arena Pharmaceuticals, Inc. Amended and Restated 2017 Long-Term Incentive Plan

. Exhibit 99.4 ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2017 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, hereby adopts the following Amended and Restated 2017 Long-Term Incentive Plan (the “Restatement”) which amends and restates the terms of the Company’s Amended and Restated 2017 Long-Term Incentive Plan that was previously in effect (the

Arena Pharmaceuticals, Inc. Amended and Restated 2017 Long-Term Incentive Plan

. Exhibit 99.4 ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2017 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, hereby adopts the following Amended and Restated 2017 Long-Term Incentive Plan (the “Restatement”) which amends and restates the terms of the Company’s Amended and Restated 2017 Long-Term Incentive Plan that was previously in effect (the

Arena Pharmaceuticals, Inc. Amended and Restated 2017 Long-Term Incentive Plan

. Exhibit 99.4 ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2017 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, hereby adopts the following Amended and Restated 2017 Long-Term Incentive Plan (the “Restatement”) which amends and restates the terms of the Company’s Amended and Restated 2017 Long-Term Incentive Plan that was previously in effect (the

Form of Nonqualified Stock Option Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

EX-99.9 9 arna-ex9996.htm FORM OF NONQUALIFIED STOCK OPTION GRANT AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN . Exhibit 99.9 Arena Pharmaceuticals, Inc. 2020 Long-Term Incentive Plan Nonqualified Stock Option Grant Agreement for Non-Employee Directors THIS GRANT AGREEMENT (this “Agreement”), effective as of (the “Gra

Form of Restricted Stock Unit Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

EX-99.8 8 arna-ex9987.htm FORM OF RESTRICTED STOCK UNIT GRANT AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Exhibit 99.8 Arena Pharmaceuticals, Inc., 2020 Long-Term Incentive Plan Restricted Stock Unit Grant Agreement for Non-Employee Directors THIS GRANT AGREEMENT (this “Agreement”), effective as of (the “Grant Date”)

Form of Restricted Stock Unit Grant Agreement under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

Exhibit 99.7 Arena Pharmaceuticals, Inc., 2020 Long-Term Incentive Plan Restricted Stock Unit Grant Agreement This Grant Agreement (this “Agreement”), effective as of (the “Grant Date”), is entered into by and between Arena Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (the “Participant”). 1.Grant of Restricted Stock Units. The Company hereby grants to the Participant Restrict

Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

Exhibit 99.5 ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, hereby adopts the following Amended and Restated 2020 Long-Term Incentive Plan which amends and restates the terms of the Company’s 2020 Long-Term Incentive Plan that was previously in effect (the “Plan”) effective as of the Effective Date

Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

Exhibit 99.5 ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, hereby adopts the following Amended and Restated 2020 Long-Term Incentive Plan which amends and restates the terms of the Company’s 2020 Long-Term Incentive Plan that was previously in effect (the “Plan”) effective as of the Effective Date

Arena Pharmaceuticals, Inc. Amended and Restated 2017 Long-Term Incentive Plan

. Exhibit 99.4 ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2017 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, hereby adopts the following Amended and Restated 2017 Long-Term Incentive Plan (the “Restatement”) which amends and restates the terms of the Company’s Amended and Restated 2017 Long-Term Incentive Plan that was previously in effect (the

Arena Pharmaceuticals, Inc. Amended and Restated 2017 Long-Term Incentive Plan

. Exhibit 99.4 ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2017 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, hereby adopts the following Amended and Restated 2017 Long-Term Incentive Plan (the “Restatement”) which amends and restates the terms of the Company’s Amended and Restated 2017 Long-Term Incentive Plan that was previously in effect (the

Form of Nonqualified Stock Option Grant Agreement for Employees and Consultants under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

Exhibit 99.6 Arena Pharmaceuticals, Inc., 2020 Long-Term Incentive Plan Nonqualified Stock Option Grant Agreement for Employees and Consultants This Grant Agreement (this “Agreement”), effective as of (the “Grant Date”), is entered into by and between Arena Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (the “Participant”). 1.Grant of Options. The Company hereby grants to the P

Form of Nonqualified Stock Option Grant Agreement for Employees and Consultants under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

Exhibit 99.6 Arena Pharmaceuticals, Inc., 2020 Long-Term Incentive Plan Nonqualified Stock Option Grant Agreement for Employees and Consultants This Grant Agreement (this “Agreement”), effective as of (the “Grant Date”), is entered into by and between Arena Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (the “Participant”). 1.Grant of Options. The Company hereby grants to the P

Form of Restricted Stock Unit Grant Agreement under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

Exhibit 99.7 Arena Pharmaceuticals, Inc., 2020 Long-Term Incentive Plan Restricted Stock Unit Grant Agreement This Grant Agreement (this “Agreement”), effective as of (the “Grant Date”), is entered into by and between Arena Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (the “Participant”). 1.Grant of Restricted Stock Units. The Company hereby grants to the Participant Restrict

Form of Restricted Stock Unit Grant Agreement under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

EX-99.7 7 arna-ex9979.htm FORM OF RESTRICTED STOCK UNIT GRANT AGREEMENT UNDER THE ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Exhibit 99.7 Arena Pharmaceuticals, Inc., 2020 Long-Term Incentive Plan Restricted Stock Unit Grant Agreement This Grant Agreement (this “Agreement”), effective as of (the “Grant Date”), is entered into by and between Arena Pharmaceuticals

Form of Restricted Stock Unit Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

EX-99.8 8 arna-ex9988.htm FORM OF RESTRICTED STOCK UNIT GRANT AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Exhibit 99.8 Arena Pharmaceuticals, Inc., 2020 Long-Term Incentive Plan Restricted Stock Unit Grant Agreement for Non-Employee Directors THIS GRANT AGREEMENT (this “Agreement”), effective as of (the “Grant Date”)

Form of Nonqualified Stock Option Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

. Exhibit 99.9 Arena Pharmaceuticals, Inc. 2020 Long-Term Incentive Plan Nonqualified Stock Option Grant Agreement for Non-Employee Directors THIS GRANT AGREEMENT (this “Agreement”), effective as of (the “Grant Date”), is entered into by and between Arena Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (the “Participant”). 1.Grant of Options. The Company hereby grants to the Par

- S-8 POS REGISTRATION NO. 333-212012

As filed with the Securities and Exchange Commission on June 19, 2020 Registration No.

- S-8 POS REGISTRATION NO. 333-218905

As filed with the Securities and Exchange Commission on June 19, 2020 Registration No.

Form of Nonqualified Stock Option Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

. Exhibit 99.9 Arena Pharmaceuticals, Inc. 2020 Long-Term Incentive Plan Nonqualified Stock Option Grant Agreement for Non-Employee Directors THIS GRANT AGREEMENT (this “Agreement”), effective as of (the “Grant Date”), is entered into by and between Arena Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (the “Participant”). 1.Grant of Options. The Company hereby grants to the Par

Form of Restricted Stock Unit Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

EX-99.8 8 arna-ex99813.htm FORM OF RESTRICTED STOCK UNIT GRANT AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Exhibit 99.8 Arena Pharmaceuticals, Inc., 2020 Long-Term Incentive Plan Restricted Stock Unit Grant Agreement for Non-Employee Directors THIS GRANT AGREEMENT (this “Agreement”), effective as of (the “Grant Date”

Form of Restricted Stock Unit Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

Exhibit 99.8 Arena Pharmaceuticals, Inc., 2020 Long-Term Incentive Plan Restricted Stock Unit Grant Agreement for Non-Employee Directors THIS GRANT AGREEMENT (this “Agreement”), effective as of (the “Grant Date”), is entered into by and between Arena Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (the “Participant”). 1.Grant of Restricted Stock Units. The Company hereby grants

Form of Nonqualified Stock Option Grant Agreement for Employees and Consultants under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

Exhibit 99.6 Arena Pharmaceuticals, Inc., 2020 Long-Term Incentive Plan Nonqualified Stock Option Grant Agreement for Employees and Consultants This Grant Agreement (this “Agreement”), effective as of (the “Grant Date”), is entered into by and between Arena Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (the “Participant”). 1.Grant of Options. The Company hereby grants to the P

Form of Nonqualified Stock Option Grant Agreement for Employees and Consultants under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

EX-99.6 6 arna-ex9969.htm FORM OF NONQUALIFIED STOCK OPTION GRANT AGREEMENT FOR EMPLOYEES AND CONSULTANTS UNDER THE ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Exhibit 99.6 Arena Pharmaceuticals, Inc., 2020 Long-Term Incentive Plan Nonqualified Stock Option Grant Agreement for Employees and Consultants This Grant Agreement (this “Agreement”), effective as of (the

Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

EX-99.5 5 arna-ex99510.htm ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Exhibit 99.5 ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, hereby adopts the following Amended and Restated 2020 Long-Term Incentive Plan which amends and restates the terms of the Company’s 2

Form of Restricted Stock Unit Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan (incorporated by reference to Exhibit 99.5 to Arena’s Registration Statement on Form S‑8, filed with the Securities and Exchange Commission on June 19, 2020, Commission File No. 333-239330)

Exhibit 99.5 Arena Pharmaceuticals, Inc., 2020 Long-Term Incentive Plan Restricted Stock Unit Grant Agreement for Non-Employee Directors THIS GRANT AGREEMENT (this “Agreement”), effective as of (the “Grant Date”), is entered into by and between Arena Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (the “Participant”). 1.Grant of Restricted Stock Units. The Company hereby grants

Form of Restricted Stock Unit Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

Exhibit 99.8 Arena Pharmaceuticals, Inc., 2020 Long-Term Incentive Plan Restricted Stock Unit Grant Agreement for Non-Employee Directors THIS GRANT AGREEMENT (this “Agreement”), effective as of (the “Grant Date”), is entered into by and between Arena Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (the “Participant”). 1.Grant of Restricted Stock Units. The Company hereby grants

Form of Nonqualified Stock Option Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

. Exhibit 99.9 Arena Pharmaceuticals, Inc. 2020 Long-Term Incentive Plan Nonqualified Stock Option Grant Agreement for Non-Employee Directors THIS GRANT AGREEMENT (this “Agreement”), effective as of (the “Grant Date”), is entered into by and between Arena Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (the “Participant”). 1.Grant of Options. The Company hereby grants to the Par

- S-8 POS REGISTRATION NO. 333-217805

As filed with the Securities and Exchange Commission on June 19, 2020 Registration No.

- S-8

As filed with the Securities and Exchange Commission on June 19, 2020 Registration No.

Form of Nonqualified Stock Option Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

. Exhibit 99.9 Arena Pharmaceuticals, Inc. 2020 Long-Term Incentive Plan Nonqualified Stock Option Grant Agreement for Non-Employee Directors THIS GRANT AGREEMENT (this “Agreement”), effective as of (the “Grant Date”), is entered into by and between Arena Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (the “Participant”). 1.Grant of Options. The Company hereby grants to the Par

Form of Restricted Stock Unit Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

Exhibit 99.8 Arena Pharmaceuticals, Inc., 2020 Long-Term Incentive Plan Restricted Stock Unit Grant Agreement for Non-Employee Directors THIS GRANT AGREEMENT (this “Agreement”), effective as of (the “Grant Date”), is entered into by and between Arena Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (the “Participant”). 1.Grant of Restricted Stock Units. The Company hereby grants

Arena Pharmaceuticals, Inc. Amended and Restated 2017 Long-Term Incentive Plan

EX-99.4 4 arna-ex9946.htm ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2017 LONG-TERM INCENTIVE PLAN . Exhibit 99.4 ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2017 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, hereby adopts the following Amended and Restated 2017 Long-Term Incentive Plan (the “Restatement”) which amends and restates the ter

Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

EX-99.2 5 arna-ex99211.htm ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Exhibit 99.2 ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, hereby adopts the following Amended and Restated 2020 Long-Term Incentive Plan which amends and restates the terms of the Company’s 2

Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

Exhibit 99.5 ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, hereby adopts the following Amended and Restated 2020 Long-Term Incentive Plan which amends and restates the terms of the Company’s 2020 Long-Term Incentive Plan that was previously in effect (the “Plan”) effective as of the Effective Date

Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

Exhibit 99.5 ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Arena Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, hereby adopts the following Amended and Restated 2020 Long-Term Incentive Plan which amends and restates the terms of the Company’s 2020 Long-Term Incentive Plan that was previously in effect (the “Plan”) effective as of the Effective Date

Form of Nonqualified Stock Option Grant Agreement for Employees and Consultants under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

Exhibit 99.6 Arena Pharmaceuticals, Inc., 2020 Long-Term Incentive Plan Nonqualified Stock Option Grant Agreement for Employees and Consultants This Grant Agreement (this “Agreement”), effective as of (the “Grant Date”), is entered into by and between Arena Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (the “Participant”). 1.Grant of Options. The Company hereby grants to the P

Form of Restricted Stock Unit Grant Agreement under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

EX-99.7 7 arna-ex99712.htm FORM OF RESTRICTED STOCK UNIT GRANT AGREEMENT UNDER THE ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Exhibit 99.7 Arena Pharmaceuticals, Inc., 2020 Long-Term Incentive Plan Restricted Stock Unit Grant Agreement This Grant Agreement (this “Agreement”), effective as of (the “Grant Date”), is entered into by and between Arena Pharmaceutical

Form of Restricted Stock Unit Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

EX-99.8 8 arna-ex9986.htm FORM OF RESTRICTED STOCK UNIT GRANT AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN Exhibit 99.8 Arena Pharmaceuticals, Inc., 2020 Long-Term Incentive Plan Restricted Stock Unit Grant Agreement for Non-Employee Directors THIS GRANT AGREEMENT (this “Agreement”), effective as of (the “Grant Date”)

Form of Restricted Stock Unit Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

Exhibit 99.8 Arena Pharmaceuticals, Inc., 2020 Long-Term Incentive Plan Restricted Stock Unit Grant Agreement for Non-Employee Directors THIS GRANT AGREEMENT (this “Agreement”), effective as of (the “Grant Date”), is entered into by and between Arena Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (the “Participant”). 1.Grant of Restricted Stock Units. The Company hereby grants

Form of Nonqualified Stock Option Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

. Exhibit 99.9 Arena Pharmaceuticals, Inc. 2020 Long-Term Incentive Plan Nonqualified Stock Option Grant Agreement for Non-Employee Directors THIS GRANT AGREEMENT (this “Agreement”), effective as of (the “Grant Date”), is entered into by and between Arena Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (the “Participant”). 1.Grant of Options. The Company hereby grants to the Par

- S-8 POS REGISTRATION NO. 333-182238

As filed with the Securities and Exchange Commission on June 19, 2020 Registration No.

- S-8 POS REGISTRATION NO. 333-160329

As filed with the Securities and Exchange Commission on June 19, 2020 Registration No.

- S-8 POS REGISTRATION NO. 333-189213

As filed with the Securities and Exchange Commission on June 19, 2020 Registration No.

Form of Nonqualified Stock Option Grant Agreement for Non-Employee Directors under the Arena Pharmaceuticals, Inc. Amended and Restated 2020 Long-Term Incentive Plan

EX-99.9 9 arna-ex99911.htm FORM OF NONQUALIFIED STOCK OPTION GRANT AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE ARENA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2020 LONG-TERM INCENTIVE PLAN . Exhibit 99.9 Arena Pharmaceuticals, Inc. 2020 Long-Term Incentive Plan Nonqualified Stock Option Grant Agreement for Non-Employee Directors THIS GRANT AGREEMENT (this “Agreement”), effective as of (the “Gr